
07/16/2025
🚨IMPORTANT UPDATE ON DCIS MANAGEMENT🚨
JAMA publication could help reshape treatment management, showing that surveillance for low risk DCIS was not inferior to the “standard of care”. The JAMA publication on results of the COMET trial, a pivotal U.S. phase III noninferiority study comparing active monitoring vs. immediate surgery in women aged 40+ with low‑risk, hormone receptor–positive, HER2–negative DCIS . With nearly 1,000 participants and ~3 years median follow‑up, results show no higher 2‑year invasive cancer rates in active. Plus, quality‑of‑life metrics were equivalent .
COMET’s significance? It challenges the “standard of care” for low‑risk DCIS and opens the door for tailored surveillance instead of overtreatment
As more evidence emerges supporting less aggressive management of low-risk DCIS, the need for non-invasive, accurate, and repeatable imaging modalities becomes even more critical for ongoing monitoring.
This is where QT Imaging’s technology could play a transformational role. Unlike traditional imaging:
✅ QT Imaging is radiation-free
✅ Offers 3D, quantitative imaging of breast tissue
✅ Comfortable, repeatable, and ideal for longitudinal tracking
✅ Particularly valuable for dense breast tissue which is a challenge mammography
Read the publication: https://jamanetwork.com/journals/jama/fullarticle/2828218